Dr. Luke Discusses Combination Approaches on Horizon in Melanoma

Video

In Partnership With:

Jason J. Luke, MD, assistant professor of Medicine, University of Chicago Medicine, discusses combination approaches that are on the horizon for the treatment of patients with melanoma.

Jason J. Luke, MD, assistant professor of Medicine, University of Chicago Medicine, discusses combination approaches that are on the horizon for the treatment of patients with melanoma.

Oncologists are starting to think about the development of combination therapies for patients with melanoma who have inflamed tumor microenvironments. Possible combinations to further augment these T cells, Luke explains, include oncolytic viruses, IDO inhibitors, and additional immune checkpoints.

However, this contrasts for patients without inflamed tumor microenvironments, because T cells need to be inserted into the tumors for PD-1/PD-L1 agents to be effective. Combination approaches for this subgroup include radiation and/or vaccines, Luke says. These two subgroups are helping oncologists think differently about drug development to maximize benefit for patients based on their immunological status, not only their molecular status.

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH